Cover Image
市場調查報告書

貓過敏:開發平台分析

Cat Allergy - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 246030
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
貓過敏:開發平台分析 Cat Allergy - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 26 Pages
簡介

貓過敏是對貓身上的過敏原產生的過敏反應。症狀有噴嚏和鼻涕、鼻塞、鼻塞造成的臉部疼痛、咳嗽、胸部壓迫感、呼吸急促、喘鳴、淚目、眼睛充血和發癢、皮疹、蕁麻疹等。

本報告提供貓過敏的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表,加上開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

貓過敏 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • ALK-Abello A/S
  • Amgen Inc.
  • Biomay AG
  • Circassia Pharmaceuticals plc

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Allergen for Cat Allergy
  • Allergen for Cat Allergy
  • BM-36
  • Epsi-Gam
  • tezepelumab
  • Vaccine for Cat Allergy
  • Vaccine for Cat Allergy

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9640IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cat Allergy - Pipeline Review, H2 2017, provides an overview of the Cat Allergy (Immunology) pipeline landscape.

Cat allergy is an allergic reaction to one or more allergens produced by cats. Symptoms include sneezing, runny or stuffy nose, facial pain (from nasal congestion), coughing, chest tightness, shortness of breath and wheezing, watery, red or itchy eyes and skin rash or hives.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cat Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cat Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cat Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 2 respectively.

Cat Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cat Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Cat Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cat Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cat Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cat Allergy (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cat Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cat Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cat Allergy - Overview
    • Cat Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Cat Allergy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cat Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Amgen Inc
    • Biomay AG
  • Cat Allergy - Drug Profiles
    • Allergen for Cat Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Cat Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Cat Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-36 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tezepelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cat Allergy - Dormant Projects
  • Cat Allergy - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cat Allergy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cat Allergy - Pipeline by ALK-Abello A/S, H2 2017
  • Cat Allergy - Pipeline by Amgen Inc, H2 2017
  • Cat Allergy - Pipeline by Biomay AG, H2 2017
  • Cat Allergy - Dormant Projects, H2 2017
  • Cat Allergy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cat Allergy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top